Investigational drug · Phase 2
Ilofotase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Open Heart Surgery.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "Ilofotase"
First trial start
2023
Dec 19, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ilofotase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Open Heart Surgery
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Ilofotase" as an intervention, largest first.
- (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKIPivotal-lookingTerminated
AM-PharmaIndustry
NCT04411472 · 676 participants · Start Nov 2, 2020 · Primary completion Aug 18, 2022
Drug: Recombinant human alkaline phosphatase · For: Acute Kidney Injury Due to Sepsis
Sites: Tucson, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 122 sites in all
- Ilofotase Alfa for Prevention of Renal Damage After Cardiac SurgeryPivotal-lookingCompleted
AM-PharmaIndustry
NCT06168799 · 271 participants · Start Dec 19, 2023 · Primary completion Oct 5, 2025
Drug: Ilofotase alfa; Placebo · For: Open Heart Surgery
Sites: Genk, Belgium; Ghent, Belgium; Roeselare, Belgium · 13 sites in all
AM-PharmaIndustry
NCT05890794 · 12 participants · Start May 15, 2023 · Primary completion Jul 7, 2023
Drug: Ilofotase Alfa, 0.8 mg/kg; Ilofotase Alfa, 3.2 mg/kg · For: Hypophosphatasia
Sites: Würzburg, Germany
Newest research
PubMed records naming it or its code names, newest first.
- A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery.
Mourisse L, Ostermann M, Thiessen S, et al. · Intensive Care Med 2026
- Plasma proteomics defines two reproducible subphenotypes of sepsis-associated acute kidney injury with distinct outcomes.
Legrand M, Nguyen H, Calfee CS, et al. · Nat Commun 2026
- A randomized Phase 1b trial evaluating the pharmacodynamics of ilofotase alfa in adults with hypophosphatasia.
Seefried L, Bernholz J, Kraan M, et al. · J Bone Miner Res 2026
- recAP administration ameliorates sepsis outcomes through modulation of gut and liver inflammation.
Macom RV, Lewellyn KZ, Strutz AG, et al. · Biochem Biophys Res Commun 2024
- Phenotype-specific therapeutic efficacy of ilofotase alfa in patients with sepsis-associated acute kidney injury.
Bruse N, Pardali K, Kraan M, et al. · Crit Care 2024
- Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).
Pickkers P, Angus DC, Bass K, et al. · Intensive Care Med 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.